We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Brg2.5
Barley Grass Research
Mostly mechanism / observational
6 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Barley Grass studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2002–2026 with a typical study size of 36 participants.
Based on 5 studies · 36 total participants
Confidence
Low confidence
By outcome
Glucose & metabolicOne small T2DM trial showed reduced LDL oxidation; animal data show improved lipid profile — but human metabolic outcomes are unproven · Unknown
Too few graded studies1 study
Steady research
1 study in the last 5 years
200220142026
1Review2026
In plain English: In conclusion, young barley preparations represent a biologically plausible functional plant food ingredient with preliminary clinical support, pending confirmation from adequately powered, standardised randomised controlled trials.
Rzeski W et al. · Molecules (Basel, Switzerland) (2026)
Agronomic variables including fertilization strategy and soil composition represent additional, underappreciated sources of phytochemical variability and safety concern.
Overall, the current evidence supports the biological plausibility of young barley as a functional plant food; yet, the clinical data remain preliminary.
Future research should prioritize preparation standardization, dose-response characterization, and agronomic transparency to strengthen translational reliability.
In plain English: Conclusion This review underscores the therapeutic potential of barley and its components in chronic disease management, highlighting the need for well-designed clinical trials to translate these findings into effective interventions.
Ali A, Ullah Z, Ullah R, Kazi M. · Heliyon (2024)
Results The finding suggests that humans digest barley starch more slowly than wheat and rice, which benefits chronic disease management.
Barley's high-molecular-weight β-glucan high content acts as a prebiotic, promotes gut health through microbiome modulation and short-chain fatty acid production, potentially preventing colon cancer and boosting immunity.
Conclusion This review underscores the therapeutic potential of barley and its components in chronic disease management, highlighting the need for well-designed clinical trials to translate these findings into effective interventions.
In plain English: Supplementation with young barley leaf extract helped scavenge oxygen free radicals and inhibit LDL oxidation, with the effect on small dense LDL strongest when combined with vitamins C and E.
36 type 2 diabetic patients received 15g barley leaf extract, vitamins C+E, or both daily for 4 weeks (three active arms, no placebo, not randomized)
Blood chemiluminescence (free-radical) levels fell in all groups; barley leaf preserved LDL vitamin E and increased oxidation lag time
Combined barley leaf + vitamins C/E most effectively inhibited small dense LDL oxidation; small, short, single trial
4Animal2019
In plain English: In high-fat-diet rats, barley grass juice reduced body weight and BMI and improved lipid profile and liver markers, with histology showing reduced atherosclerosis.
In plain English: Barley grass extract inhibited breast and prostate cancer cell viability and induced apoptosis by raising intracellular reactive oxygen species in vitro.
Woo SM, Kwon SC, Ko SG, Cho SG. · Biomed Rep (2017)
Barley grass extract reduced viability of breast and prostate cancer cell lines (MTT assay)
Induced apoptosis via increased intracellular ROS, blocked by the antioxidant N-acetyl-cysteine
In-vitro cell study only; no relevance established for whole-body human outcomes